BEIJING--(BUSINESS WIRE)--Novo Holdings, a leading global life science investor, and KKR, a leading global investment firm, today announced the signing of definitive agreements under which Novo ...

Novo Nordisk NVO has seen strong momentum in recent years, driven by the commercial success of its blockbuster semaglutide products, Wegovy (obesity) and Ozempic (diabetes). Building upon this ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks that Jim Cramer discusses. In a prior call, a viewer asked about Novo Nordisk A/S ...

annualized bleeding rates and additional studies including thrombin generation with concizumab in hemophilia A/B "At Novo Nordisk, we believe understanding the whole person and their journey is ...

Much like the long-term users of its most popular product, Novo Nordisk's (NYSE: NVO) stock has slimmed down considerably of late. Share prices of the company, which developed and sells weight ...

Novo Nordisk and the Obesity Association are teaming up to help educate patients and doctors about this issue. The Obesity Association is a division of the American Diabetes Association. The ...

Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include the “very rare” risk of non-arteritic anterior ischemic optic neuropathy.

Almost exactly a year after launching its Obesity Association, the American Diabetes Association (ADA) has recruited Novo Nordisk for support. The ADA’s obesity division went live last June ...